Pharmacopeia licenses cardio compounds from BMS

Pharmacopeia acquired exclusive rights to certain lead and backup DARA (dual angiotensin and endothelin receptor antagonist) development candidates, and plans to initiate preclinical development studies immediately.

“This is an opportunity to pursue an exciting class of compounds resulting from a program focused on creating a single molecule that combines the activity of two clinically validated therapeutic classes, both of which have been demonstrated to be efficacious in cardiovascular disease. As such, the DARA compounds are first-in-class and have the potential to advance clinical practice,” commented Dr David Floyd, executive vice president and chief scientific officer of Pharmacopeia.

Under the terms of the agreement, Pharmacopeia will provide Bristol-Myers Squibb with a set of compound libraries and further pay Bristol-Myers Squibb milestone payments upon the achievement of clinical and regulatory milestones, and royalties on sales of products, if any, resulting from the program.